Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2012

View Archived Issues

Astellas presents promising in vitro and in vivo results for a novel antifungal agent

Boehringer Ingelheim presents new PDE9A inhibitors

Indian researchers disclose novel agents for cancer

New agents for parasitic infections patented by U.S. team

SRI-011225 shows favorable toxicology and efficacy profile in vitro

Synergy Pharmaceuticals files IND for GC-C agonist

Vascular Pharmaceuticals raises funds to support development of VPI-2690B

Concert Pharmaceuticals discloses novel deuterated hydroxybutyrate analogues

New antiviral agents patented by German researchers

Cancer Therapeutics CRC synthesizes novel agents for cancer

Amitiza approved in U.K. for chronic idiopathic constipation

First-in-human results presented for a novel anti-HIV-1 vaccine

Takeda obtains U.K. license for erectile dysfunction medication

Kyowa Hakko Kirin to return Busulfex rights

Xtandi now available in the U.S.

Zealand Pharma's dual-acting candidate enters phase I trial

Critical Outcome Technologies and Delmar Chemicals sign R&D collaboration

PSAP evaluated as a new urinary biomarker for monitoring Fabry's disease

Primary endpoint met in first stage of phase II Reolysin trial

First phase finishes in endometrial regenerative cell therapy project

Phase III study of Androxal enrolls first patients

FDA approves production of [11C]-choline injection for PET imaging

Phase II study begins of GBR-500 in ulcerative colitis

DSMB recommends continuation of Prana's IMAGINE trial

Pivotal pharmacokinetic study of BEMA-buprenorphine/naloxone meets objectives

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 6, 2025.
Regenxbio’s Duchenne gene therapy data positive as shares falter
BioWorld
Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
EMA warns Ozempic linked to ‘very rare’ side effect
BioWorld
The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...
Aiatella secures €2M for AI-based cardiovascular imaging tech
BioWorld MedTech
Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...